Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 12;12:1756284819853790. doi: 10.1177/1756284819853790

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2019

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 2. — Frequency of individuals with at least one reimbursement in 2016 for gastrointestinal therapeutic drugs, depending on diseases and other health conditions.

A02A: antacids; A02BC: PPIs; A02BX: other drugs for peptic ulcer and gastro-oesophageal reflux disease; A02X: other drugs for acid-related disorders; A03: drugs for functional gastrointestinal disorders; A04: antiemetics and antinauseants, A06: drugs for constipation, A07: antidiarrhoeals, intestinal anti-inflammatory/anti-infective agents.

^*Excluding ischaemic heart disease, cerebrovascular disease, heart failure, peripheral vascular disease, diabetes, end-stage renal disease.

^**Excluding mental illness.

°People with at least six reimbursements per year and with no other diseases, other chronic treatments or pregnancy during the year.

CV, cardiovascular; HIV, human immunodeficiency virus; NSAIDs, nonsteroidal anti-inflammatory drugs; PPIs, proton-pump inhibitors.